AdultPediatricDosage Forms & Strengths injection, lyophilized powder for reconstitution 100mg/vial (Remicade, Inflectra, Renflexis, Ixifi, Avsola) Biosimilars to Remicade Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Ixifi (infliximab-qbtx) Avsola (infliximab-axxq) Rheumatoid Arthritis Remicade, Inflectra, Renflexis, Ixifi, Avsola Indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately-to-severely active rheumatoid arthritis in combination with methotrexate 3 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter If incomplete response is noted, dose may be increased to 10 mg/kg OR increasing the dosing frequency to q4Weeks Psoriatic Arthritis Remicade, Inflectra, Renflexis, Ixifi, Avsola Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis 5 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter May be used with methotrexate Plaque Psoriasis Remicade, Inflectra, Renflexis, Ixifi, Avsola Indicated for the treatment of adult patients with chronic severe (ie, extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate Should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician 5 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter Can be used with or without methotrexate Crohn Disease Remicade, Inflectra, Renflexis, Ixifi, Avsola Indicated for moderately-to-severely active Crohn disease in patients who have had inadequate response to conventional therapy Also, indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn disease 5 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg Patients who do not respond by Week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue Ulcerative Colitis Remicade, Inflectra, Renflexis, Ixifi, Avsola Indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adults with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks Ankylosing Spondylitis Remicade, Inflectra, Renflexis, Ixifi, Avsola Indicated for reducing signs and symptoms in patients with active ankylosing spondylitis 5 mg/kg IV at 0, 2, and 6 weeks, THEN q6Weeks thereafter Idiopathic Pulmonary Fibrosis (Orphan) Treatment of idiopathic pulmonary fibrosis Orphan indication sponsor Foundation for Fatal Rare Diseases; Herrengasse 21; Furstentum Liechtenstein; Germany Dosage Modifications Moderate-to-severe (NYHA class III or IV) heart failure: Not to exceed 5 mg/kg/dose (see Contraindications) Dosing Considerations Prior to initiating treatment and periodically during therapy, patients should be evaluated for active tuberculosis and tested for latent infection Higher incidence of serious infections in infliximab-treated patients ≥65 years; use with cautionDosage Forms & Strengths injection, lyophilized powder for reconstitution 100mg/vial (Remicade, Inflectra, Renflexis, Ixifi, Avsola) Biosimilars to Remicade Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Ixifi (infliximab-qbtx) Avsola (infliximab-axxq) Crohn Disease Remicade, Inflectra, Renflexis, Ixifi, Avsola Reduction of signs and symptoms and induction and maintenance of clinical remission in pediatric patients aged ≥6 year with moderately to severely active Crohn disease who have had inadequate response to conventional therapy <6 years: Not studied ≥6 to 17 years: 5 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter Ulcerative Colitis Remicade, Inflectra, Renflexis, Ixifi, Avsola Treatment of moderately to severely active ulcerative colitis in children aged ≥6 yr who have had inadequate response to conventional therapy <6 years: Not studied ≥6 years: 5 mg/kg IV at 0, 2, and 6 weeks, THEN q8Weeks thereafter Dosing considerations Due to risk of hepatosplenic T-cell lymphoma, a careful risk-benefit assessment should be made when drug is used in combination with other immunosuppressants in pediatric UC patients Juvenile Rheumatoid Arthritis (Orphan) Orphan indication sponsor Centocor, Inc; 200 Great Valley Parkway; Malvern, PA 19355-1307 Dosing Considerations Children should be current with immunizations before starting infliximab Do not administer live vaccines while patient is taking infliximabInteraction CheckerEnter a drug name and infliximabNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (1)upadacitinibinfliximab, upadacitinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated.Serious - Use Alternative (76)abataceptabatacept, infliximab. Mechanism: pharmacodynamic synergism. Contraindicated. Increased risk of serious infection.adalimumabadalimumab and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.alefaceptalefacept and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.anakinraanakinra and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.anthrax vaccineinfliximab decreases effects of anthrax vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.antithymocyte globulin equineantithymocyte globulin equine and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.antithymocyte globulin rabbitantithymocyte globulin rabbit and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.axicabtagene ciloleucelinfliximab, axicabtagene ciloleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.azathioprineazathioprine and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.baricitinibbaricitinib, infliximab. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Baricitinib is not recommended in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressives.basiliximabbasiliximab and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.BCG vaccine liveinfliximab decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.brexucabtagene autoleucelinfliximab, brexucabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.canakinumabcanakinumab and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.certolizumab pegolinfliximab and certolizumab pegol both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid combination because of an increased risk of serious infection.ciltacabtagene autoleucelinfliximab, ciltacabtagene autoleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.cyclosporinecyclosporine and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.diphtheria & tetanus toxoidsinfliximab decreases effects of diphtheria & tetanus toxoids by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.diphtheria & tetanus toxoids/ acellular pertussis vaccineinfliximab decreases effects of diphtheria & tetanus toxoids/ acellular pertussis vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccineinfliximab decreases effects of diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.etanerceptetanercept and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.everolimuseverolimus and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.glatiramerglatiramer and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.golimumabgolimumab and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.hepatitis A vaccine inactivatedinfliximab decreases effects of hepatitis A vaccine inactivated by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.hepatitis a/b vaccineinfliximab decreases effects of hepatitis a/b vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.hepatitis a/typhoid vaccineinfliximab decreases effects of hepatitis a/typhoid vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.hepatitis b vaccineinfliximab decreases effects of hepatitis b vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.human papillomavirus vaccine, nonavalentinfliximab decreases effects of human papillomavirus vaccine, nonavalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.human papillomavirus vaccine, quadrivalentinfliximab decreases effects of human papillomavirus vaccine, quadrivalent by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines.hydroxychloroquine sulfatehydroxychloroquine sulfate and infliximab both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.idecabtagene vicleucelinfliximab, idecabtagene vicleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.influenza virus vaccine quadrivalentinfliximab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.influenza virus vaccine quadrivalent, adjuvantedinfliximab decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.influenza virus vaccine quadrivalent, cell-culturedinfliximab decreases effects of influenza virus vaccine quadrivalent, cell-cultured by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.influenza virus vaccine quadrivalent, intranasalinfliximab decreases effects of influenza virus vaccine quadrivalent, intranasal by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.influenza virus vaccine trivalentinfliximab decreases effects of influenza virus vaccine trivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.influenza virus vaccine trivalent, adjuvantedinfliximab decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine.Japanese encephalitis virus vaccineinfliximab decreases effects of Japanese encephalitis virus vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.leflunomideinfliximab and leflunomide both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.lisocabtagene maraleucelinfliximab, lisocabtagene maraleucel. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.measles (rubeola) vaccineinfliximab decreases effects of measles (rubeola) vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.measles mumps and rubella vaccine, liveinfliximab decreases effects of measles mumps and rubella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.measles, mumps, rubella and varicella vaccine, liveinfliximab decreases effects of measles, mumps, rubella and varicella vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.meningococcal A C Y and W-135 polysaccharide vaccine combinedinfliximab decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.muromonab CD3infliximab and muromonab CD3 both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.mycophenolateinfliximab and mycophenolate both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.pexidartinibinfliximab and pexidartinib both increase Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity.pneumococcal vaccine 13-valentinfliximab decreases effects of pneumococcal vaccine 13-valent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.pneumococcal vaccine heptavalentinfliximab decreases effects of pneumococcal vaccine heptavalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.pneumococcal vaccine polyvalentinfliximab decreases effects of pneumococcal vaccine polyvalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.pretomanidinfliximab, pretomanid. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid.rabies vaccineinfliximab decreases effects of rabies vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants may interfere with development of active immunity.rabies vaccine chick embryo cell derivedinfliximab decreases effects of rabies vaccine chick embryo cell derived by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.rilonaceptinfliximab and rilonacept both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.rotavirus oral vaccine, liveinfliximab decreases effects of rotavirus oral vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.rubella vaccineinfliximab decreases effects of rubella vaccine by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.selinexorselinexor, infliximab. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.sirolimusinfliximab and sirolimus both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.smallpox (vaccinia) vaccine, liveinfliximab decreases effects of smallpox (vaccinia) vaccine, live by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines.tacrolimusinfliximab and tacrolimus both increase immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug.temsirolimusinfliximab and temsirolimus